CSF3 and neutropenia: Subsequently, Oshita F et al. compared a group of 60 patients with unresectable lung cancer who were randomly assigned to prophylactic G-CSF administration when monocytopenia appeared (group A) or G-CSF administration when neutropenia (< 1,000/microl) or leukopenia (< 2000/microl) appeared after chemotherapy (group B) [14].